31 results about "Insulin delivery device" patented technology

In an automated insulin delivery device, fuzzy logic may be applied to the responding to the possibility of a user taking additional action that may affect the blood glucose concentration. Fuzzy sets may be defined for empirically derived different likelihoods of the user taking such additional action based on correlated factors. A membership function may be provided for each fuzzy set. The membership function may provide a probability of membership in the set based on a parameter. Each fuzzy set may have a response that is reflective of the likelihood of additional user action associated with the fuzzy set. The responses by the AID device to each of these cases may reflect the probability of each such case occurring as evidenced by empirical data.

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Some methods and systems may be configured to adjust insulin delivery to a person with diabetes according to one or more conditions of an insulin delivery device. Some methods and systems may be configured to enable a lock-out mode where adjustment to insulin delivery to personalize automated insulin delivery is restricted.

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Some methods and systems may be configured to adjust insulin delivery to a person with diabetes according to one or more conditions of an insulin delivery device. Some methods and systems may be configured to enable a lock-out mode where adjustment to insulin delivery to personalize automated insulin delivery is restricted.

The exemplary embodiments may modify a glucose cost component of the cost function of the control loop of an insulin delivery device to compensate for persistent positive low level glucose excursions relative to a target glucose level. The exemplary embodiments may enable use of different glucose cost component functions for different glucose levels of the user. These glucose cost component functions may be employed in piecewise fashion with a different piece being applied for each respective range of glucose level values for the user. The final glucose cost function for calculating the glucose cost component may be a weighted combination of a piecewise glucose cost function and a weighted standard cost function (such as a quadratic function). The weights may reflect the magnitude and / or persistence of glucose excursions relative to a target glucose level.

Methods of insulin delivery may include selecting a basal insulin delivery rate responsive to a projected blood glucose level that approximates a target blood glucose level. Methods of insulin delivery may further include generating insulin delivery instructions for an insulin delivery device, the insulin delivery instructions corresponding to the basal insulin delivery rate and for a variable time duration relative to an intended time duration.

A method may comprise (a) inserting an insulin delivery device subcutaneously into a body of a subject, which comprises an amperometric glucose sensor comprising an electrode layer comprising an indicating electrode and underlying a redox-catalytic layer comprising a redox mediator; (b) using said insulin delivery device to deliver an insulin formulation (e.g., comprising a phenol or cresol excipient) subcutaneously to said subject; and (c) using said amperometric glucose sensor to measure a subcutaneous glucose concentration, which comprises using said redox-catalytic layer to allow electron transfer from subcutaneous glucose to said indicating electrode sufficient to cause a response of said amperometric glucose sensor at an applied bias potential of no more than +250 millivolts, wherein (b) and (c) are performed at the same time for at least one hour, while maintaining a sensor sensitivity of at least 50% of an initial sensor sensitivity for up to one hour.

In an aspect, the present disclosure provides a method comprising: (a) positioning an insulin delivery device on a body of a subject via a single puncture site in said body of said subject; (b) using said insulin delivery device to deliver an insulin or insulin analog formulation to said subject via said single puncture site; and (c) using a sensor of said insulin delivery device to measure a glucose concentration in said body of said subject via said single puncture site, wherein (b) and (c) are performed at substantially the same time for a time period of at least 1 hour subsequent to said positioning in (a), while maintaining a sensitivity of said sensor of at least 50% of an initial sensitivity of said sensor.

Exemplary embodiments relate to drug delivery devices, such as automated insulin delivery (AMD) devices. The described methods and apparatuses allow an AMD device to be initialized and / or operated with little or no user input. Exemplary logic initializes the AMD device to operate with known-safe drug delivery parameters that leverage the AMD device's ability to monitor blood glucose levels at short intervals and continuously deliver small amounts of insulin. The AMD then rapidly adapts the parameters and system constraints based on current and historical glucose measurements. Further embodiments provide for the detection of events that result in disturbances to glucose control, and to adaptation of alert frequency based on user behavior.

An insulin delivery device includes an insulin injection device in communication with a controller for controlling the insulin injection device. The controller is configured to receive a heart signal from one or more heart sensors, and a blood glucose signal from one or more blood glucose sensors. The controller is further configured to analyze changes in the heart rhythm of the subject based on the heart signal and determine, based on the changes in the heart rhythm and the blood glucose signal, whether the subject is and / or will be experiencing an adverse event. Upon determination that the subject is or will be experiencing an adverse event, the controller determines one or more parameters of delivery of insulin to be delivered to the subject. Finally, the controller is configured to control the injection device to deliver insulin to the subject in accordance with the determined one or more parameters of delivery.

A method may comprise (a) inserting an insulin delivery device subcutaneously into a body of a subject, which comprises an amperometric glucose sensor comprising an electrode layer comprising an indicating electrode and underlying a redox-catalytic layer comprising a redox mediator; (b) using said insulin delivery device to deliver an insulin formulation (e.g., comprising a phenol or cresol excipient) subcutaneously to said subject; and (c) using said amperometric glucose sensor to measure a subcutaneous glucose concentration, which comprises using said redox-catalytic layer to allow electron transfer from subcutaneous glucose to said indicating electrode sufficient to cause a response of said amperometric glucose sensor at an applied bias potential of no more than +250 millivolts, wherein (b) and (c) are performed at the same time for at least one hour, while maintaining a sensor sensitivity of at least 50% of an initial sensor sensitivity for up to one hour.

The exemplary embodiments may modify a glucose cost component of the cost function of the control loop of an insulin delivery device to compensate for persistent positive low level glucose excursions relative to a target glucose level. The exemplary embodiments may enable use of different glucose cost component functions for different glucose levels of the user. These glucose cost component functions may be employed in piecewise fashion with a different piece being applied for each respective range of glucose level values for the user. The final glucose cost function for calculating the glucose cost component may be a weighted combination of a piecewise glucose cost function and a weighted standard cost function (such as a quadratic function). The weights may reflect the magnitude and / or persistence of glucose excursions relative to a target glucose level.

An analyte monitoring system and method for an on-body sensor control device may have the ability to sense two or more analytes of a patient, the sensor control device comprising a processor and a memory, there are instructions for determining various machine states and outputs based on time-dependent sensor data for each analyte. The status and output may include: alarm conditions for one or more analytes; consulting a message; a correction of the analyte state estimate; indication of failure of the sensor control device, failure of the insulin delivery device, drug dose calculation; or analyzing the report. Examples of systems and methods for dual analytes including glucose and ketones are described. Data may be transmitted from the sensor control device to the reader device for output to a user.

A technique for treating diabetes that recognizes patient insulin sensitivity is a time-varying physiological parameter. The described techniques for treating diabetes include measuring interstitial fluid glucose concentration, reading insulin delivery data, determining patient insulin sensitivity based on the interstitial fluid glucose concentration and insulin delivery data, and a time-varying physiological parameter, and dispensing an insulin dose from an insulin delivery device based on the determined patient insulin sensitivity.

A technique for treating diabetes that recognizes patient insulin sensitivity is a time-varying physiological parameter. The described techniques for treating diabetes include measuring interstitial fluid glucose concentration, reading insulin delivery data, determining patient insulin sensitivity based on the interstitial fluid glucose concentration and insulin delivery data, and a time-varying physiological parameter, and dispensing an insulin dose from an insulin delivery device based on the determined patient insulin sensitivity.

The present disclosure is directed to automated-insulin-delivery (AID) systems, devices and methods. Specifically, in some aspects, an AID device / patch includes a housing having an adhesive tape, an insulin pump including a single lumen cannula, a glucose sensor including a flat probe, a processor, and an automated-insulin-delivery algorithm (AIDA). In some embodiments, the housing is configured to be adhered the skin of a user via the adhesive tape and house the insulin pump, glucose sensor, and AIDA, the probe at least partially resides within the cannula, and the AIDA is configured as computer instructions operating on the processor causing the processor to control insulin delivery by the insulin pump according to glucose levels determined in subcutaneous tissue based on signals received from the glucose sensor.

Techniques disclosed herein relate to managing operations of a dual-mode insulin delivery device that can operate in a manual insulin delivery mode and an automated closed-loop insulin delivery mode. In one example, a processor-implemented method includes obtaining insulin delivery data of an insulin delivery device collected while the insulin delivery device operates in a closed-loop mode, determining an updated value of a parameter of the insulin delivery device in a manual mode based on the insulin delivery data, and causing the insulin delivery device to deliver insulin in the manual mode based on the updated value of the parameter of the insulin delivery device, where the parameter of the insulin delivery device has separate values in the manual mode and the closed-loop mode.

In an aspect, the present disclosure provides an insulin delivery device configured to be positioned on a body of a subject via a single puncture site in said body of said subject, wherein said insulin delivery device is configured to deliver an insulin or insulin analog formulation to said subject via said single puncture site, wherein said insulin delivery device comprises a sensor configured to measure a glucose concentration in said body of said subject via said single puncture site, and wherein said delivering and said measuring are performed at substantially the same time for a time period of at least 1 hour subsequent to said positioning, while maintaining a sensitivity of said sensor of at least 50% of an initial sensitivity of said sensor.

Analyte monitoring systems and methods for on-body sensor control devices are capable of sensing two or more analytes in a patient and include a processor and memory with instructions for determining various machine states and outputs based on time-correlated sensor data for each analyte. The states and outputs may include warning conditions, advisory messages, corrections to analyte status estimates, indications of sensor control device failure, insulin delivery device failure, drug dose calculations, or analysis reports for one or more analytes. An example system and method is described for dual analytes including glucose and ketones. Data may be transmitted from the sensor control device to a reader for output to a user.

One or more embodiments of the present disclosure may include an insulin delivery system that includes an insulin delivery device, a user interface that includes multiple user-selectable icons or buttons each representing different meal characteristics, memory to store one or more user-specific dosage parameter, and a processor in communication with the memory and adapted to receive blood glucose data. The processor may also be adapted to determine initial meal characteristics associated with each of the user-selectable icons or buttons based on at least one of the user-specific dosage parameters. The processor may also be adapted to update the meal characteristics associated with each of the user-selectable icons or buttons based upon the blood glucose data.

Exemplary embodiments relate to drug delivery devices, such as automated insulin delivery (AMD) devices. The described methods and apparatuses allow an AMD device to be initialized and / or operated with little or no user input. Exemplary logic initializes the AMD device to operate with known-safe drug delivery parameters that leverage the AMD device's ability to monitor blood glucose levels at short intervals and continuously deliver small amounts of insulin. The AMD then rapidly adapts the parameters and system constraints based on current and historical glucose measurements. Further embodiments provide for the detection of events that result in disturbances to glucose control, and to adaptation of alert frequency based on user behavior.

In an aspect, the present disclosure provides an insulin delivery device configured to be positioned on a body of a subject via a single puncture site in said body of said subject, wherein said insulin delivery device is configured to deliver an insulin or insulin analog formulation to said subject via said single puncture site, wherein said insulin delivery device comprises a sensor configured to measure a glucose concentration in said body of said subject via said single puncture site, and wherein said delivering and said measuring are performed at substantially the same time for a time period of at least 1 hour subsequent to said positioning, while maintaining a sensitivity of said sensor of at least 50% of an initial sensitivity of said sensor.

The application relates to the technical field of biomedical engineering, and particularly discloses a portable insulin administration device, which comprises a non-invasive blood glucose detection module arranged from bottom to top and used for monitoring human blood glucose concentration based on a counter-ion electro-osmosis technology; a drug loading module used for loading drugs, wherein the drugs comprise insulin; and a transdermal administration module connected with the drug loading module and used for applying a pulse voltage to skin to enhance the transdermal penetration efficiency of the skin and drive the drugs in the drug loading module to penetrate into a dermis layer when the monitored blood glucose concentration value is greater than a preset threshold value. The device adopts the counter-ion electro-osmosis technology to monitor the human blood glucose concentration in real time, and realizes transdermal delivery of insulin through the electroporation technology, so that the two functions of blood glucose concentration monitoring and insulin delivery are combined, the integration of symptom diagnosis and treatment is realized, and both functions can be realized in a completely non-invasive manner without causing damage to the skin of a patient.

Abstract A monitoring feature, such as, for example, a pen cap, for an insulin delivery device may include at least one circuit adapted to detect at least one of a capping or decapping of the pen cap from an insulin pen and a processor for using information to the at least one of a capping or decapping of the pen cap. A monitoring feature for an insulin delivery device includes at least one circuit adapted to detect use of the insulin delivery device. USER Sensor Sensor Data Data GLUCOSE SENSOR SYSTEM 101 v SECOND FIRST ACCESSORY ACCESSORY MOBILE 103 102 APPLICATION g 104 MANUEL MANUEL DELIVERY DELIVERY DEVICE DEVICE 107 106 108 WEB x SERVICES 105 FIG. 1A 20 24 22 75 63 23 O ct 2 02 4 2 0 2 4 2 2 7 5 6 3 2 3 O c t 2 0 2 4 U S E R S e n s o r S e n s o r W O 2 0 1 9 / 1 1 8 5 3 1 D a t a G L U C O S E D a t a S E N S O R S Y S T E M 1 0 1 S U B S T I T U T E S H E E T ( R U L E 2 6 ) F I R S T S E C O N D A C C E S S O R Y A C C E S S O R Y M O B I L E 1 0 2 1 0 3 A P P L I C A T I O N 1 / 3 9 1 0 4 M A N U E L M A N U E L D E L I V E R Y D E L I V E R Y D E V I C E D E V I C E 1 0 6 1 0 7 1 0 8 W E B S E R V I C E S 1 0 5 P C T / U S 2 0 1 8 / 0 6 5 0 6 7 F I G . 1 A

An example system for therapy delivery includes one or more processors configured to, in response to a determination that a meal event is to occur, perform the following: output instructions to an insulin delivery device for delivering a portion of a therapy dose; outputting instructions to a device for notifying the patient to use the insulin delivery device to ingest the partial therapy dose; or outputting instructions to the insulin delivery device for preparing the partial therapy dose prior to the occurrence of the meal event; and in response to a determination indicating that the meal event is occurring, performing the following: outputting an instruction to an insulin delivery device for delivering a remaining therapy dose; outputting instructions to the device for notifying the patient to use the insulin delivery device to ingest the remaining therapy dose; or outputting an instruction to the insulin delivery device to prepare the remaining therapy dose.

An example system for therapy delivery includes one or more processors configured to in response to a prediction indicating that the meal event is to occur, output instructions to an insulin delivery device to deliver a partial therapy dosage, to a device to notify the patient to use the insulin delivery device to take the partial therapy dosage, or to the insulin delivery device to prepare the partial therapy dosage prior to the meal event occurring, and in response to a determination indicating that the meal event is occurring (e.g., based on movement characteristics of a patient arm), output instructions to the insulin delivery device to deliver a remaining therapy dosage, to the device to notify the patient to use the insulin delivery device to take the remaining therapy dosage, or to the insulin delivery device to prepare the remaining therapy dosage.

The present disclosure relates to a system for closed loop control of glycemia. In one arrangement, the system comprises: an insulin delivery device; a user interface for inputting patient data, the patient data including a basal insulin profile, an insulin-to-carbohydrate ratio, and meal data; and a controller in communication with the user interface and the insulin delivery device and configured to receive glucose data. The controller is further configured to execute: estimating an amount of active insulin in the patient, the active insulin not including the basal insulin profile, determining a meal carbohydrate value from the meal data, estimating a physiological glucose for the patient and a rate of change of physiological glucose based in part on the glucose data, determining an attenuation factor based on the physiological glucose and the rate of change of the physiological glucose, determining a meal bolus based on meal data, the insulin-to-carbohydrate ratio, and the determined attenuation factor, modifying the determined meal bolus based on the estimated amount of active insulin in the patient, and transmitting a request to deliver the modified meal bolus to the insulin delivery device.

A method may include displaying at least three icons on a user interface of a mobile device, including a first icon associated with the at least three icons associated with a first carbohydrate level, a second icon associated with the at least three icons associated with a second carbohydrate level, and a third icon associated with the at least three icons associated with a third carbohydrate level. The method may also include receiving a user selection of one of the three icons through the user interface of the mobile device, and determining an insulin bolus level from the user selection. The method may also include communicating the insulin bolus level to an insulin delivery device.

Disclosed herein are techniques related to determination of adjustments to fluid delivery settings. In some embodiments, the techniques may involve accessing insulin delivery data for a user of an insulin delivery device. The insulin delivery data may be indicative of an amount of insulin delivered by the insulin delivery device to the user during a time period. The techniques may also involve analyzing the insulin delivery data to generate an updated insulin sensitivity factor (ISF) value. The techniques may further involve generating, based on the updated ISF value, a recommendation to adjust an ISF value of the insulin delivery device. Additionally, the techniques may involve causing adjustment of the ISF value to the updated ISF value in accordance with the recommendation.

One or more embodiments of the present disclosure may include an insulin delivery system that includes an insulin delivery device, a user interface that includes multiple user-selectable icons or buttons each representing different meal characteristics, memory to store one or more user-specific dosage parameter, and a processor in communication with the memory and adapted to receive blood glucose data. The processor may also be adapted to determine initial meal characteristics associated with each of the user-selectable icons or buttons based on at least one of the user-specific dosage parameters. The processor may also be adapted to update the meal characteristics associated with each of the user-selectable icons or buttons based upon the blood glucose data.

A method may include displaying at least three icons on a user interface of a mobile device, including a first icon associated with the at least three icons associated with a first carbohydrate level, a second icon associated with the at least three icons associated with a second carbohydrate level, and a third icon associated with the at least three icons associated with a third carbohydrate level. The method may also include receiving a user selection of one of the three icons through the user interface of the mobile device, and determining an insulin bolus level from the user selection. The method may also include communicating the insulin bolus level to an insulin delivery device.